Limited information is available regarding the impact of prior use of inhaled corticosteroids (ICS) in patients subsequently developing community-acquired pneumonia (CAP). We assessed the effects of prior ICS use on severity of illness and microbiology in CAP hospitalized patients.
METHODS:
A retrospective cohort study of subjects with CAP (by the International Classification of Diseases, 9th Revision, Clinical Modification) was conducted over a 4-year period at 2 tertiary teaching hospitals. Subjects were considered to be ICS users if they received ICS prior to admission. Primary outcomes were severity of illness and microbiology at admission.
RESULTS:
Data were abstracted on 664 subjects: 89 prior ICS users (13.4%) and 575 non-users (86.6%). Prior ICS users had higher severity of illness at admission: mean ± SD Pneumonia Severity Index 100.8 ± 31.4 vs 68.8 ± 33.4, P = .001, and CURB-65 (confusion, urea nitrogen, respiratory rate, blood pressure, ≥ 65 years of age) score 1.56 ± 1.02 vs 1.19 ± 1.02, P = .002. Prior ICS use was independently associated with antimicrobial-resistant pathogens: 11.2% vs 5.9%, odds ratio 2.6, 95% CI 1.1–6.1, P = .04.
CONCLUSIONS:
Prior ICS use was associated with higher severity of illness at admission and higher incidence of antimicrobial-resistant pathogens in CAP hospitalized patients.
CalverleyP, PauwelR, VestboJ, JonesP, PrideN, GulsikA, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet, 2003; 361(9356):449-456. Erratum in: Lancet 2003;361(9369):1660.
5.
NanniniLJ, CatesCJ, LassersonTJ, PooleP. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2007;(4):CD003794.
6.
CalverleyPMA, AndersonJA, CelliB; TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 2007; 356(8):775-789.
7.
KardosP, WenckerM, GlaabT, VogelmeierC. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2007; 175(2):144-149.
8.
WedzichaJA, CalverleyPMA, SeemungalTA, HaganG, AnsariZ, StockleyRA; INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med, 2008; 177(1):19-26.
9.
ErnstP, GonzalezAV, BrassardP, SuissaS. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med, 2007; 176(2):162-166.
10.
DrummondMB, DasenbrookEC, PitzMW, MurphyDJ, FanE. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA, 2008; 300(20):2407-2416.
11.
SinghS, AminAV, LokeYK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med, 2009; 169(3):219-229.
12.
SinghS, LokeYK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in COPD: A critical review and update. Curr Opin Pulm Med, 2010; 16(2):118-122.
13.
Malo de MolinaR, MortensenEM, RestrepoMI, CopelandLA, PughMJ, Anzuetoa. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalized with pneumonia. Eur Respir J, 2010; 36(4):751-757.
14.
SinganayamanA, ChalmersJD, AkramAR, HillAT. Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur Respir J, 2011; 38(1):36-41.
15.
ChenD, RestrepoMI, FineMJ, PughMJ, AnzuetoA, MeterskyML, et al. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med, 2011; 184(3):312-316.
16.
StuckAE, MinderCE, FreyFJ. Risk of infectious complications in patients taking glucocorticoids. Rev Infect Dis, 1989; 11(6):954-963.
17.
ConesaD, RelloJ, VallésJ, MariscalD, FerreresJC. Invasive aspergillosis: a life-threatening complication of short-term steroid treatment. Ann Pharmacother, 1995; 29(12):1235-1237.
18.
MaskellNa, WaineDJ, LindleyA, PepperellJC, WakefieldAE, MillerRF, DaviesRJ. Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study. Thorax, 2003; 58(7):594-597.
19.
FalgueraM, CarratalàJ, Ruiz-Gonzalez, Garcia-VidalC, GazquezI, DorcaJ, et al. Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli. Respirology, 2009; 14(1):105-111.
20.
SousaD, JustoI, DominguezA, ManzurA, IzquierdoC, RuizL, et al. Community-acquired pneumonia in immunocompromised older patients: incidence, causative organisms and outcome. Clin Microbiol Infect, 2013; 19(2):187-192.
21.
NiedermanMS, MandellLA, AnzuetoA, BarlettJG, CampbellGD, DeanNC, et al; American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention. Am J Respir Crit Care Med, 2001; 163(7):1730-1754.
22.
MagiorakosAP, SrinivasanA, CareyRB, CarmeliY, FalagasME, GiskeCG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect, 2012; 18(3):268-281.
23.
FineMJ, AubleTE, YealeyDM, HanusaBH, WeissfeldLA, SingerDE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med, 1997; 336(4):243-250.
24.
LimWS, LewisS, MacfarlaneJT. Severity prediction rules in community-acquired pneumonia: a validation study. Thorax, 2000; 55(3):219-223.
25.
RestrepoMI, MortensenEM, AnzuetoA. Are COPD patients with pneumonia who are taking inhaled corticosteroids at higher risk of dying?. Eur Respir J, 2011; 38(1):1-3.
26.
CrimC, CalverleyPMA, AndersonJA, CelliB, FergussonGT, JenkinsC. Pneumonia risk in COPD patients receiving inhaled inhaled corticoesteroids alone or in combination: TORCH study result. Eur Respir J, 2009; 34(3):641-647.
27.
SinganayagamA, ChalmersJD, HillAT. Inhaled corticoesteroids and risk of pneumonia: evidence for and against the proposed association. QJM, 2010; 103:379-385.
28.
SethiS, MurphyTF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med, 2008; 359(22):2355-2365.
LiapikouA, PolverinoE, EwigS, CillonizC, MarcosMA, MensaJ, et al. Severity and outcomes of hospitalized community-acquired pneumonia in COPD patients. Eur Respir J, 2012; 39(4):855-861.
31.
MarinA, MonsoE, Garcia-NunezM, SauledaJ, NogjeraA, PonsJ, et al. Variability and effects of bronchial colonization in patients with moderate COPD. EurRespir J, 2010; 35(2):295-302.
32.
CostelloeC, MetcalfeC, LoveringA, MantD, HayAD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ, 2010; 340:c2096.
